A Phase 1 Study of SAHA (NSC 701852 IND 71976) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors

Trial Profile

A Phase 1 Study of SAHA (NSC 701852 IND 71976) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs Vorinostat (Primary) ; Isotretinoin
  • Indications CNS cancer; Leukaemia; Lymphoma; Medulloblastoma; Neuroblastoma; Rhabdoid tumour; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 May 2008 Status changed from suspended to in progress as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top